Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03992326 2021-03-18

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Phase 1 Terminated

6 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT02070406 2019-02-28

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase 1 Terminated

4 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01409174 2017-05-31

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Phase 1 Terminated

19 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00569296 2015-03-25

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Phase 1 Terminated

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00054405 2013-04-09

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Phase 1 Terminated

40 enrolled

CNS

Neuroblastoma

NCT00091611 2012-10-26

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1 Terminated

3 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01106235 2011-12-21

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 1 Terminated

12 enrolled

Dermatologic

Melanoma

Clinical Trials

ELiPSE-1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

FT516 in Subjects With Advanced Hematologic Malignancies

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

CD19

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma